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Background.  Complicated urinary tract infections (cUTIs) are responsible for a major share of all antibiotic consumption in 
hospitals. We aim to describe risk factors for treatment failure and mortality among patients with cUTIs.
Methods. A multinational, multicentre retrospective cohort study, conducted in 20 countries in Europe and the Middle East. 
Data were collected from patients’ files on hospitalised patients with a diagnosis of cUTI during 2013-2014. Primary outcome was 
treatment failure, secondary outcomes included 30 days all-cause mortality,among other outcomes. Multivariable analysis using a 
logistic model and the hospital as a random variable was performed to identify independent predictors for these outcomes.
Results.  A total of 981 patients with cUTI were included. Treatment failure was observed in 26.6% (261/981), all cause 30-day 
mortality rate was 8.7% (85/976), most of these in patients with catheter related UTI (CaUTI). Risk factors for treatment failure in 
multivariable analysis were ICU admission (OR 5.07, 95% CI 3.18-8.07), septic shock (OR 1.92, 95% CI 0.93-3.98), corticosteroid 
treatment (OR 1.92, 95% CI 1.12-3.54), bedridden (OR 2.11, 95%CI 1.4-3.18), older age (OR 1.02, 95% CI 1.0071.03-), metastatic 
cancer (OR 2.89, 95% CI 1.46-5.73) and CaUTI (OR 1.48, 95% CI 1.04-2.11). Management variables, such as inappropriate empirical 
antibiotic treatment or days to starting antibiotics were not associated with treatment failure or 30-day mortality. More patients with 
pyelonephritis were given appropriate empirical antibiotic therapy than other CaUTI [110/171; 64.3% vs. 116/270; 43%, p <0.005], 
nevertheless, this afforded no advantage in treatment failure rates nor mortality in these patients.
Conclusions. In patients with cUTI we found no benefit of early appropriate empirical treatment on survival rates or other 
outcomes. Physicians might consider supportive treatment and watchful waiting in stable patients until the causative pathogen is 
defined. 
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 Urinary tract infections (UTIs) are responsible for a major share 
of antibiotic consumption in hospitals [1, 2]. Complicated UTI 
(cUTI), as defined by the US Food and Drug Administration 
(FDA), applies to pyelonephritis or UTI in a host with predis-
posing conditions [3]. In patients with cUTI, infections are 
frequently caused by multidrug-resistant gram negative bacilli 
[4–7]. Bacterial resistance to antimicrobial agents has been 
identified in the European Union and many other countries as a 
major public health problem [8–11].
The presentation of patients with cUTI is changing over time 
while patients’ characteristics are also changing: patients are 
older, with a high prevalence of comorbidities, instrumentation 
of the urinary tract, and polypharmacy, and with highly resis-
tant pathogens [12, 13]; contemporary data are scarce.
We conducted a multicenter retrospective study looking for 
risk factors for treatment failure and a fatal outcome among 
hospitalized patients with cUTI. The study was performed in 
hospitals with a high incidence of cUTI caused by resistant 
pathogens, mainly extended-spectrum β-lactamase (ESBL)–
carrying gram-negative bacteria. We focused on patients’ 
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characteristics, comorbidities, infection presentation, type 
of UTI, clinical management during hospitalization, and the 
impact of inappropriate empirical antibiotic treatment.
METHODS
Patients and Study Design
This is a multinational retrospective cohort study using patient 
charts for data collection. The study was conducted in Bulgaria 
(2 hospitals), Greece (2 hospitals), Hungary (3 hospitals), Israel 
(3 hospitals), Italy (3 hospitals), Romania (2 hospitals), Spain 
(3 hospitals), and Turkey (2 hospitals). We collected data on 
hospitalized patients who had a diagnosis of cUTI as the pri-
mary cause of hospitalization and patients hospitalized for 
another reason but who developed cUTI during their hospi-
talization, from 1 January 2013 to 31 December 2014. Patients 
were identified by searching for the appropriate International 
Classification of Diseases, Ninth or Tenth Revision, Clinical 
Modification codes [14, 15] at discharge on the hospital admin-
istration system [16]; inclusion and exclusion criteria were 
applied to these patients.
Inclusion criteria were patients with UTI and at least 1 of 
the following: indwelling urinary catheter, urinary retention, 
neurogenic bladder, obstructive uropathy, renal impairment 
caused by intrinsic renal disease, renal transplantation, uri-
nary tract modifications, or pyelonephritis with normal uri-
nary tract anatomy. UTI was defined in the presence of at 
least 1 of the following signs or symptoms: chills or rigors 
associated with fever or hypothermia, flank pain (pyelone-
phritis) or pelvic pain (cUTI), dysuria or urinary frequency/
urgency, costovertebral angle tenderness on physical exam-
ination, and either urine culture with at least ≥105 colo-
ny-forming units (CFU)/mL of a uropathogen (no more than 
2 species) or at least 1 blood culture growing possible uro-
pathogens (no more than 2 species) with no other evident 
site of infection. Only 1 episode per patient was included in 
the present analysis.
We retrieved demographic, bacteriological, and clinical data 
including baseline patient characteristics, comorbidities, place 
of acquisition of infection, predisposing risk factors, signs and 
symptoms of infection, laboratory and microbiological data, 
imaging test data, and infection management data including 
empirical antibiotic therapy, outcomes, details of discharge, 
readmission, and where applicable, date of death. The follow-up 
period was defined for up to 2 months after discharge. We used 
the following categories:
• UTI related to indwelling urinary catheterization, including 
long-term, short-term, and intermittent catheterization.
• Pyelonephritis: inflammation of the kidney tissue caused 
by bacterial infection in patients who have no other uri-
nary tract modification, defined as sepsis, flank pain, or 
tenderness and no other urinary tract pathology.
• UTI related to anatomical urinary tract modification, 
including any urinary diversion procedure, nephrostomy 
or stents, or renal transplants.
• UTI related to obstructive uropathy, including any obstruc-
tion intrinsic or extrinsic to the urinary tract, such as stones, 
tumor, ureteral herniation, and prostate hyperplasia.
• UTI related to other events, including UTI that does not 
fulfill any other category.
Screening for ESBLs was defined as an isolate resistant to cef-
tazidime. If growth was detected in blood and urine, with differ-
ent resistance patterns, blood cultures were given priority over 
urine cultures and screening for ESBL was defined by growth in 
blood cultures.
Our primary outcome was treatment failure, defined as any of 
the following conditions:
• Signs or symptoms of cUTI present at diagnosis that have 
not improved by day 5–7 of appropriate antibiotic therapy.
• New cUTI-related symptoms that have developed within 
30 days of the original cUTI diagnosis.
• Urine culture taken within 30  days of the original cUTI 
diagnosis, either during or after completion of therapy, that 
grew ≥104 CFU/mL of the original pathogen identified in 
the diagnostic sample.
• Death irrespective of cause within 30 days of the original 
cUTI diagnosis.
Thirty-day and 2-month mortality and adverse events were col-
lected as secondary outcomes. Secondary outcomes, defined 
and analyzed only in patients alive at day 30, included time to 
clinical response, duration of antibiotic therapy, positive urine 
culture within 30 days, signs or symptoms not resolved by day 7, 
length of hospital stay, and readmissions to the hospital within 
60 days of hospital discharge.
For data collection, an access-controlled, web-based elec-
tronic case report form was used. For confirmation of data 
quality, study sites were monitored and audited by a designated 
local third party.
Statistical Methods
We assumed a 20% treatment failure rate. A sample size of 1000 
patients (approximately 40–60 patients per hospital) is sufficient 
to introduce 20 independent risk factors for treatment failure in 
a multivariable analysis. This assumption was calculated using 
the rule of 10 outcomes per 1 risk factor [17].
For univariate analysis, categorical variables were compared 
using χ2 test or Fisher exact test, as appropriate. Normally 
distributed continuous variables were compared using t test, 
otherwise by Mann-Whitney U test. Normality of continuous 
variable was examined by the Kolmogorov-Smirnov test and by 
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was used to test for homogeneity of odds ratio (OR), to look for 
interactions of appropriate and inappropriate empirical treat-
ment effect in subgroups with bacteremia and septic shock.
Multivariable analysis was performed to identify indepen-
dent predictors for treatment failure and 30-day mortality. We 
used generalized estimating equation binary logistics to account 
for study site as a random-effects variable. Co-linearity was 
tested by a correlation matrix and variables with strong correla-
tions (Spearman correlation coefficient >0.6) were omitted after 
clinical consideration. Missing data were handled by multiple 
imputations. The analysis was based on the assumption that the 
covariates were missing at random. Ten imputed data sets were 
created. All statistically significant covariates (Tables 1 and 3) 
were entered in the imputation model including variables that 
are predictive of the missing values [18].
The interaction of appropriate empirical treatment with 
the type of infection, Charlson score, functional capacity, 
and septic shock was tested; however, the interactions were 
not significant and were removed from the final model. For 
model fitting we used the quasi-likelihood under the inde-
pendence model criterion. For each outcome (treatment 
failure and 30-day mortality) we tested 6 different models in 
order to fit the best model.
Statistical analysis was conducted using the IBM SPSS statis-
tics 24 software. All reported P values are 2-sided and statistical 
significance was set at P < .05.




No Treatment Failure 
(n = 720)
Treatment Failure 
(n = 261) P  Value 
Patient characteristics
 Sex (male) 449 (45.8) 136 (52.1) 313 (43.5) .016
 Age, y, median (IQR) 68 (56–80) 72 (59–83) 67 (55–78.75) .000
 Admission reason: other condition than UTI 351 (35.8) 133 (51) 128 (30.3) .000
 Place of residency: medical care facility 179 (18.2) 60 (23) 119 (16.5) .021
 Previous 30-d antibiotic treatment 189/980 (19.3) 46 (17.6) 143/719 (19.9) .427
 Functional capacity: bedridden 158 (16.2) 68 (26.2) 90 (12.5) .000
 Corticosteroid therapy 67 (6.8) 26 (10) 41 (5.7) .019
 Previous UTI infection within a year 239/980 (24.4) 63 (24.1) 176/719 (24.5) .913
 Acquisition site: hospital 194 (19.8) 76 (29.1) 118 (16.4) .000
Comorbidities
 Charlson score, median (IQR) 2 (1–4) 3 (1–5) 2 (0–4) .000
 Dementia 134/980 (13.7) 43/260 (16.5) 91 (12.6) .117
 Chronic kidney disease 273 (27.8) 84 (32.2) 189 (26.3) .067
 Diabetes mellitus 263 (26.8) 70 (26.8) 193 (26.8) .996
 Metastatic cancer 48 (4.9) 23 (8.8) 25 (3.5) .001
 Cancer 176 (17.9) 65 (24.9) 111 (15.4) .001
Infection presentation
 Septic shock (yes) 34/916 (3.7) 17/243 )7) 17/672 (2.5) .002
 ICU admission 136 (13.9) 81 (31) 55 (7.6) .000
 Bacteremia 190 (19.4) 45 (17.2) 145 (20.1) .310
Type of UTI infection
 Catheter associated 336 (34.3) 199 (27.6) 137 (52.5) .000
 Pyelonephritis 197 (20.1) 169 (23.5) 28 (10.7)
 Other 448 (45.7) 352 (48.9) 96 (36.8)
Infection management
 Appropriate empirical treatment 429/806 (53.2) 97/211 (46) 332/595 (55.8) .014
 Days to antibiotic treatment start, median, (IQR) 0 (0–1) 0 (0–1) 0 (0–1) .006
UTI pathogen n = 976 n = 259 n = 717
 Acinetobacter baumannii 27 (2.8) 18 (6.95) 9 (1.25) .000
 Pseudomonas aeruginosa 82 (8.4) 30 (11.6) 52 (7.3)
 Klebsiella pneumoniae 146 (15) 47 (18.1) 99 (13.8)
 Enterococcus spp 54 (5.5) 21 (8.1) 33 (4.6)
 Proteus mirabilis 73 (7.5) 26 (10) 47 (6.6)
 Escherichia coli 518 (53.1) 93 (35.9) 425 (59.3)
 Other 76 (7.8) 24 (9.3) 52 (7.3)
 Extended-spectrum β-lactamases 201 (20.5) 59 (22.6) 142 (19.7) .323
Data are presented as No. (%) unless otherwise indicated.
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Ethical Considerations
The study was approved by the local research ethics committee of 
each site. The processing of the personal data of patients was ano-
nymized and complied with local data protection legislation and 
with the European Directive on the Privacy of Data (95/46/EC).
RESULTS
The demographic and clinical characteristics of the 981 
included patients are shown in Table 1. The median age of the 
cohort was 68  years (interquartile range [IQR], 56–80  years); 
45.8% (449/981) were male, 18.2% (179/981) came from 
medical care facilities, and 16.2% (158/981) were bedrid-
den. Catheter-associated UTI (CaUTI) accounted for 34.4% 
(340/981) of infections, and 20% (197/981) were diagnosed as 
acute pyelonephritis.
Treatment Failure
Treatment failure was observed in 26.6% (261/981) of patients; 
52.5% (137/261) in patients with CaUTI, 10.7% (28/261) in 
pyelonephritis, and 36.8% (96/261) in other UTIs (P = .001).
In univariate analysis, patients had higher failure rates if they 
were older, admitted for other conditions than UTI, bedrid-
den, and with higher Charlson scores (Table 1). Patients who 
received early appropriate empirical antibiotic treatment had 
a lower risk of treatment failure compared with patients who 
did not receive appropriate empiric antibiotic treatment (46% 
[97/211] vs 55.8% [332/595]; P  =  .014). Bacteremia did not 
influence the risk for treatment failure; neither did pathogens 
positive on screening for ESBLs. Acinetobacter baumannii and 
Pseudomonas aeruginosa were associated with higher failure 
rates and Escherichia coli associated with a lower rate.
In multivariable analysis for treatment failure, ICU admission 
(OR, 5.07; 95% confidence interval [CI], 3.18–8.07), septic shock 
(OR, 1.92; 95% CI, .93–3.98), corticosteroid treatment (OR, 1.92; 
95% CI, 1.12–3.54), functional capacity (bedridden) (OR, 2.11; 
95% CI, 1.4–3.18), older age (OR [increment of 1  year], 1.02; 
95% CI, 1.007–1.03), metastatic cancer (OR, 2.89; 95% CI, 1.46–
5.73), and CaUTI (OR, 1.48; 95% CI, 1.04–2.11) were found to 
be independent predictors of treatment failure (Table 2). When 
ICU is taken out of the model, septic shock becomes statistically 
significant (OR, 2.59; 95% CI, 1.24–5.39; P = .011). There was no 
strong correlation between these 2 parameters, and a model not 
taking ICU into account was inferior. Management variables, 
such as appropriate empirical antibiotic treatment or days to 
starting antibiotics, were not associated with treatment failure, 
nor were other comorbidities (Table 2).
Thirty-day Mortality
The all-cause 30-day mortality rate was 8.7% (85/976). Factors 
associated with 30-day mortality on univariate analysis are 
shown in Table 3.
Appropriate empirical antibiotic therapy did not influence 
30-day mortality (36/69 [52.2%] vs 391/733 [53.3%]; P = .85); 
neither did pathogens positive on screening for ESBLs (12/85 
[14%] in those who died vs 188/891 [21%] in those who did 
not; P = .128).
On multivariable analysis, risk factors for 30-day mortality 
were bedridden patients (OR, 2.22; 95% CI, 1.2–4.09), age (OR 
for 1 additional year of age, 1.05; 95% CI, 1.03–1.08), malig-
nancy (OR, 2.55; 95% CI, 1.38–4.73), residency in a medical 
care facility (OR, 2.08; 95% CI, 1.12–3.86), patients admitted 
due to other condition (OR, 2.95; 95% CI, 1.55–5.61), pre-
senting with septic shock (OR, 7.87; 95% CI, 3.19–19.37), and 
needing invasive mechanical ventilation (OR, 9.71; 95% CI, 
4.46–21.1). Management variables, such as appropriate empiri-
cal antibiotic treatment or days to starting antibiotics, were not 
associated with 30-day mortality (Table 4).
UTI Subgroups
When differentiating patients by type of infection, treatment 
failure and 30-day mortality were higher in CaUTI than in 
pyelonephritis: 40% (137/336) vs 14.2% (28/197) and 15.9% 
(53/334) vs 2% (4/196), respectively. Twenty-seven percent of 
patients with pyelonephritis had bacteremia (54/198), com-
pared to 19.7% with indwelling urinary catheters (67/340) 
and 15.7% (71/451) with other cUTI (P = .003). More patients 
with pyelonephritis were given appropriate empirical antibiotic 
therapy than other CaUTI (110/171 [64.3%] vs 116/270 [43%]; 
P < .005), but this did not improve treatment failure or mortal-
ity rates (Supplementary Table 1).
Secondary Outcomes
The time to clinical response was 3 days (IQR, 2–5 days), and 
did not differ between types of UTI. Median length of hos-
pital stay was 7  days (IQR, 5–13  days), and was shorter in 
Table 2. Multivariable Analysis for Treatment Failure
Risk Factor
Multivariable Generalized 
Estimating Equation,  
OR (95% CI) P  Value
Metastatic cancer 2.89 (1.46–5.73) .02
Septic shock 1.92 (.93–3.98) .079
Infection source:  
indwelling catheter
1.48 (1.04–2.11) .028
Appropriate treatmenta 0.81 (.57–1.15) .246
Duration of symptoms before  
hospitalization
0.99 (.97–1.02) .656
Corticosteroid therapy 1.92 (1.12–3.54) .018
Functional capacity: bedridden 2.11 (1.4–3.18) .000
Age (per 1 y) 1.02 (1.007–1.03) .001
ICU admission  5.07 (3.18–8.07) .000
Hospital introduced as a random-effects variable, goodness of fit; quasi-likelihood under the 
independence model criterion = 966.74, constant β = –2.094.
Abbreviations: CI, confidence interval; ICU, intensive care unit; OR, odds ratio.
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pyelonephritis (6 days; IQR, 4–10 days) than in CaUTI (9 days; 
IQR, 5–17  days). Median duration of antibiotic therapy was 
6 days (IQR, 4–10 days), and did not differ between types of 
UTI. Sixteen percent of the patients (156/966) were rehospital-
ized within 60 days (Table 5 and Supplementary Table 2).
DISCUSSION
Patients with complicated UTI had a treatment failure rate of 
27% and a 30-day mortality rate of 9%, most of these due to 
CaUTI. Risk factors for treatment failure and 30-day mortality 
were older patients, bedridden and metastatic cancer patients, 
CaUTI as source of infection, and unstable patients presenting 
with septic shock or admitted to ICU for both outcomes. Higher 
body weight, coming from medical care facilities and admitted 
for a different reason than UTI, and need for mechanical venti-
lation were additional risk factors for 30-day mortality and cor-
ticosteroid therapy or treatment failure. Management variables, 
such as inappropriate empirical antibiotic treatment or days to 
starting antibiotics, were not associated with treatment failure 
or 30-day mortality.
Table 3. Risk Factors for 30-day Mortality
Characteristic 30-d Mortality (Yes) (n = 85) 30-d Mortality (No) (n = 891) P  Value
Patient characteristics
 Sex (male) 36 (42.2) 412 (46.2) .49
 Age, y, median (IQR) 79 (65–87) 67 (55–79) .000
 Admission reason: other condition 56 (65.9) 294 (33) .000
 Place of residency: medical care facility 30 (35.3) 147 (16.5) .000
 Previous 30-d antibiotic treatment 12 (14.1) 176 (19.8) .207
 Functional capacity: bedridden 33 (39.3) 122 (13.7) .000
 Corticosteroid therapy 9 (10.6) 58 (6.5) .155
 Previous UTI infection within a year 16 (18.8) 223/890 (25.1) .202
 Acquisition site: hospital 28 (32.9) 166 (18.6) .002
 Indwelling urinary catheter at admission 30 (35.3) 187 (21) .002
Comorbidities
 Charlson score, median (IQR) 3 (2–6) 2 (0–4) .000
 Congestive heart failure 27 (31.8) 154 (17.3) .001
 Dementia 23 (27.1) 109 (12.2) .000
 Chronic kidney disease 30 (35.3) 241 (27) .105
 Chronic pulmonary disease 20 (23.5) 120 (13.5) .011
 Diabetes mellitus 23 (27.1) 238 (26.7) .945
 Metastatic cancer 11 (12.9) 37 (4.2) .000
 Active chemotherapy 6 (7.1) 24/890 (2.7) .026
 Cancer 27 (31.8) 149 (16.7) .001
 Renal impairment 29/83 (34.9) 218/891 (88.3) .036
Infection presentation
 Septic shock (yes) 14 (17.3) 20 (2.4) .000
 ICU admission 33 (38.8) 103 (11.6) .000
 Invasive mechanical ventilation 32 (37.6) 62 (7) .000
Type of UTI infection
 Catheter associated 53 (62.4) 281 (31.5) .000
 Pyelonephritis 4 (4.7) 192 (21.5)
 Other 28 (32.9) 418 (46.9)
Infection management
 Appropriate empirical treatmenta 36/69 (52.2) 391/733 (53.3) .85
UTI pathogen
 Acinetobacter baumannii 5 (6) 20 (2.3) .002
 Pseudomonas aeruginosa 7 (8.3) 75 (8.5)
 Klebsiella pneumoniae 15 (17.9) 130 (14.7)
 Enterococcus spp 8 (9.5) 46 (5.2)
 Proteus mirabilis 13 (15.5) 60 (6.8)
 Escherichia coli 30 (35.7) 487 (54.9)
 Other 6 (7.1) 69 (7.8)
 Extended-spectrum β-lactamases 12 (14.1) 188 (21.1) .128
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ICU, intensive care unit; IQR, interquartile range; UTI, urinary tract infection.
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We looked for the influence of appropriate empirical treat-
ment in subgroups of very ill patients (patients with bactere-
mia or septic shock), but could not find a significant effect. 
Significantly more patients with pyelonephritis were given 
appropriate empirical antibiotic therapy than with CaUTI (64% 
vs 43%; P < .005); nevertheless, appropriate empirical antibiotic 
treatment afforded no advantage in treatment failure rates nor 
in 30-day mortality in these patients.
Regarding pathogens, A. baumannii and P. aeruginosa were 
associated with higher failure rates. The response of these 
pathogens to treatment might be slower, but we might not have 
captured all patient-associated risk factors for treatment fail-
ure, and these pathogens might reflect a different population 
of patients.
Few studies have been performed to define and character-
ize risk factors for treatment failure in cUTI and pyelonephritis. 
Pertel and Haverstock [19] retrospectively analyzed data on 522 
adult patients from 2 prospective clinical trials designed to eval-
uate antibiotic regimens for urinary tract infections. Treatment 
failure rate was 15% overall; significant predictors for failure 
were hospitalization, the presence of resistant organism(s), dia-
betes mellitus, and a history of kidney stones. Failure rate was 
53% for patients with at least 1 of these 4 risk factors. Patients 
in our study were all inpatients and therefore a different popu-
lation. Efstathiou et al [20] retrospectively assessed 225 patients 
with cUTI and pyelonephritis and found recent hospitalization, 
previous use of antibiotics, and immunosuppression to be inde-
pendent correlates for a resistant pathogen, which correlated 
with treatment failure. Additional predictors included nephro-
lithiasis in women and a history of recurrent UTI in men. None 
of these studies discussed management variables or empirical 
antibiotic treatment.
Reviewing the literature, the range of mortality rates in com-
plicated UTI is very broad (2%–33%) [20–23], derived from the 
different compositions of included patients. In a recent study 
by Babich et al studying 315 hospitalized patients with CaUTI, 
mortality rate was 30.8% in a cohort consisting of old patients 
[24]. Lower mortality rate is seen in studies including strictly 
pyelonephritis and higher in studies including a more hetero-
geneous group of patients. All studies define their patients as 
cUTI or pyelonephritis but actually the inclusion criteria dif-
fer significantly, as do the outcomes, all raising doubt if these 
conditions should be combined in randomized controlled tri-
als (RCTs) and emphasizing the need to separate these popu-
lations by explicit definitions. To note, the FDA and European 
Medicines Agency (EMA) differ in their recommended trial 
populations for cUTI RCTs. The FDA considers pyelonephritis 
an important subset of cUTI and states that approximately 30% 
or more of the clinical trial population should be patients with 
pyelonephritis for an indication for “treatment of complicated 
urinary tract infections including pyelonephritis [3].” EMA pre-
fers that efficacy in acute pyelonephritis be studied separately 
and, if studied together, recommends stratification at enroll-
ment and limiting the proportion with pyelonephritis.
The balance between preventing patients’ deaths from sepsis 
and using antibiotics judiciously to prevent resistance develop-
ment is largely determined by our belief in the benefit of appro-
priate empirical antibiotic treatment and the magnitude of the 
benefit [25]. Physicians try hard to treat patients with suspected 
infections with appropriate empirical therapy as soon as possi-
ble. This has a price of administering superfluous and unnec-
essary antibiotics, which has been proven to be associated with 
the rise of resistant pathogens, side effects, and no benefit for 
the individual patient and society [26].
Previous studies have found a significant association of 
early appropriate empirical treatment for bacteremia, sep-
sis, or septic shock with patient survival [27–30]. We found 
no impact of appropriate empirical treatment on treatment 
Table 5. Secondary Outcomes
Outcome No (%) of Episodes
In- hospital mortality 91/989 (9.2)
All-cause mortality within 30 d 85/976 (8.7)
All the other components of the  
composite primary outcome
 Positive urine culture within 30 d 72/984 (7.3)
 Signs/symptoms not resolved by day 7 251/988 (25.4)
 All-cause mortality for 2 mo after  
hospital discharge
36/989 (3.6)
 Readmission to the hospital within  
60 d of hospital discharge
156/966 (16.1)
 Adverse events related to antibiotic treatment 73/986 (7.4)
Continuous variables Median (IQR)
 Time to clinical response 3 (2–5)
 Length of hospital stay, d 7 (5–13)
 Duration of antibiotic therapy, d 6 (4–10)
Abbreviation: IQR, interquartile range.
Table 4. Multivariable Analysis for 30-day Mortality
Risk Factor
Multivariable Logistic 
Regression Analysis,  
OR (95% CI) P Value
Septic shock 7.87 (3.19–19.37) .000
Infection source
 Pyelonephritis Reference category
 Other 2.4 (.85–6.73) .096
 Indwelling catheter 2.7 (.91–8.02) .073
Place of residency: medical care facility 2.08 (1.12–3.86) .020
Admission reason: other condition 2.95 (1.55–5.61) .001
Weight (per 1 kg) 0.79 (.64–.99) .037
Cancer 2.55 (1.38–4.73) .003
Invasive mechanical ventilation 9.71 (4.46–21.1) .000
Functional capacity: bedridden 2.22 (1.2–4.09) .010
Age (per 1 y) 1.05 (1.03–1.08) .000
Hospital introduced as a random-effects variable, goodness of fit; quasi-likelihood under the 
independence model criterion = 426.848, constant β = –.727.
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failure or mortality. In a systematic review and meta-analy-
sis of prospective studies, inappropriate empirical antibiotic 
treatment for sepsis was associated with a higher risk for a 
fatal outcome (OR, 1.6; 95% CI, 1.37–1.86) [29]. Most patients 
in these studies included all types of bacteremia and no 
study specifically applied to cUTI patients. UTIs are unique, 
especially in the CaUTI population, as it is often difficult to 
distinguish between symptomatic UTI and febrile illness 
from another source with asymptomatic bacteriuria, a very 
common finding. After 1 month of using a urinary catheter, 
almost 100% of patients will be colonized with bacteria [30]. 
Any febrile episode without a clear source in these patients 
might be regarded as CaUTI. Babich et al showed that appro-
priate empirical treatment did not change outcomes of long-
term survival in patients with CaUTI (hazard ratio, 0.99; 95% 
CI, .75–1.3) [24].
Reisfeld et al examined the impact of appropriate empirical 
treatment on mortality among patients with cognitive decline 
and gram-negative bacteremia and found that appropriate 
empirical treatment was not associated with mortality benefit in 
the sickest subgroup of patients with decubitus ulcers [31]. The 
knowledge that appropriate empirical treatment is not associ-
ated with improved survival or treatment success among stable, 
non-ICU patients may allow holding back antibiotic therapy in 
these patients until better understanding the cause of fever and 
culture results.
Our study has several limitations: It is a retrospective study, 
in which each site enrolled 40–60 patients. Therapy decisions 
were taken by the attending physician, who managed patients 
according to local practice. Hospitals might differ in their 
threshold for admission, management, and coding of diagno-
ses. We tried to correct for this by using a strict and detailed 
protocol for collection of data; monitoring; and in the analysis 
by adding site as a random variable in our analysis. Another 
limitation might be overfitting of the model for mortality. We 
entered 10 variables into the model predicting 30-day demises 
in 85 patients. The strength of our study is the large sample size, 
the fact that it is multinational and multicenter, and our analy-
sis by UTI subgroups and management variables that were not 
emphasized in previous publications.
Further research is needed in patients with cUTI, and espe-
cially in the group of patients with urinary catheters, to define 
the subgroup with a higher certainty of a UTI infection as the 
cause of fever (or other complaints) vs the group of patients 
with bacteriuria but fever of other origins, in which antibiotic 
treatment can be deferred. Septic shock emerged here (as in 
other studies) as an important determinant for treatment fail-
ure and a fatal outcome. Better management of septic shock is 
paramount; unfortunately, we have witnessed no major prog-
ress in the recent past. Further research is warranted to assess 
whether the response of different pathogens to treatment is 
truly different.
In conclusion, in a large cohort of patients with compli-
cated UTIs, we found no benefit of early appropriate empiri-
cal treatment on survival rates or other outcomes. Physicians 
might consider supportive treatment and watchful waiting in 
stable patients until the cause of sepsis is clear and the causative 
pathogen is defined.
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